Acceleron Pharma (XLRN) Tops Q3 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
Go back to Acceleron Pharma (XLRN) Tops Q3 EPS by 10c
November 4, 2015 7:01 AM EST
ACE-083 Phase 1 results demonstrate an unprecedented increase in
muscle volume. Phase 2 clinical trials planned to start next year
ACE-2494 generates significant increases in muscle mass in
preclinical studies. Phase 1 clinical trial of ACE-2494 planned
to start next year
FDA granted Fast Track Designation for dalantercept in combination
with axitinib for the treatment of patients with advanced renal cell
carcinoma
Phase 3 clinical trials with luspatercept in lower risk
myelodysplastic syndromes and beta-thalassemia expected to begin by
year-end 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Acceleron Pharma Inc. (NASDAQ:... More
November 4, 2015 6:58 AM EST
CAMBRIDGE, Mass., Nov. 4, 2015 /PRNewswire/ -- Flagship Ventures, a leading venture capital and venture creation firm focused on innovations in healthcare and sustainability, announced it has launched Evelo Therapeutics, a new company focused on leveraging the power of the microbiome to develop novel therapies for cancer, with an initial capital commitment of $35 million.
Evelo is pioneering Oncobiotic therapeutics, a new modality in cancer therapy based on the cancer microbiome. Evelo is the first company to systematically... More
